PRB Costs Allowable Whether Measured Under FAS 106 or IRS Criteria
Client Alert | 1 min read | 09.23.09
To address the "catch-22" confronted by contractors using the accrual method of calculating post-retirement benefit (PRB) costs for financial reporting purposes who have had to choose either to fund the entire amount of PRB costs measured in accordance with Financial Accounting Standard (FAS) 106 in order to be reimbursed for the costs on Government contracts, or to fund only the amount of PRB costs deductible under the Internal Revenue Code (IRC) and thereby forgo reimbursement of the full FAS 106 amount, the FAR has been amended, under a final rule effective January 11, 2010, to allow contractors the option to measure accrued post-retirement benefit (PRB) costs using either the criteria in FAS 106 or the criteria in IRC 419. The final rule also (1) addresses the transition period when a change is made from one accrual accounting method to another by requiring the contractor to treat the change in unfunded accumulated PRB obligation as a gain or loss and demonstrate that there will be no duplicate recovery of costs as a result of the change; (2) expressly states that any prior period unfunded accrual is unallowable under either method of accrual accounting; and (3) clarifies that use of a health care assumption for measurement of costs is required unless prohibited by IRC welfare benefit fund rules.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
